,Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes
0,prerank,MSigDB_Hallmark_2020__Oxidative Phosphorylation,0.5329993825185703,1.652696996507016,0.0,0.4067611114488965,0.161,33/128,9.69%,COX8A;LDHA;ATP5PF;COX4I1;ATP6V0E1;ATP5PO;COX7C;COX6B1;ATP5MC3;COX17;ATP5MF;COX6C;ATP5PD;ATP5F1B;GPI;UQCRQ;COX6A1;ATP5F1A;UQCRB;COX5A;COX7A2L;UQCR10;CYB5R3;POR;UQCRC1;ACAA1;ATP5MC1;COX7B;CYCS;SLC25A5;CYC1;HSD17B10;NDUFS4
1,prerank,KEGG_2021_Human__Cardiac muscle contraction,0.6520641481553732,1.5267959646893698,0.01834862385321101,0.6466224843436493,0.44,16/26,9.23%,COX8A;COX4I1;COX7C;COX6B1;UQCRHL;COX6C;UQCRQ;COX6A1;UQCRB;COX5A;COX7A2L;UQCR10;UQCRC1;COX7B;TPM3;CYC1
2,prerank,KEGG_2021_Human__Insulin secretion,-0.8547681646046366,-1.4855686196877205,0.002680965147453083,0.6170919118631363,0.413,6/15,11.67%,ATF4;PRKCB;VAMP2;CREB5;GNAQ;ATP1A1
3,prerank,KEGG_2021_Human__cAMP signaling pathway,-0.7044325548434672,-1.4403370992428635,0.009846827133479213,0.8148777810500388,0.709,9/58,11.67%,RAC1;RAP1A;ROCK1;PPP1R12A;CALM1;CALM2;CREB5;EP300;ATP1A1
4,prerank,KEGG_2021_Human__Adherens junction,-0.771412550349852,-1.4348296363325679,0.020481927710843374,0.6041992033531751,0.746,7/28,14.07%,RAC1;IQGAP1;WAS;TGFBR2;EP300;VCL;SRC
5,prerank,KEGG_2021_Human__Protein processing in endoplasmic reticulum,-0.6776139827006479,-1.429308406644804,0.004158004158004158,0.5080899217334655,0.78,9/93,8.86%,HSP90AB1;ATF4;UBE2D2;UBE2D3;DNAJA1;HSP90AA1;UBQLN1;SEC61B;NFE2L2
6,prerank,KEGG_2021_Human__Amphetamine addiction,-0.7841110491795298,-1.420122086150432,0.025348542458808618,0.4840039981080382,0.832,7/22,9.79%,ATF4;CALM1;PPP3CA;PRKCB;CALM2;CREB5;PPP3R1
7,prerank,MSigDB_Hallmark_2020__UV Response Dn,-0.7243591920879019,-1.4171336197694373,0.011534025374855825,0.42619192108496273,0.84,8/37,10.06%,PTEN;TGFBR2;ANXA4;SYNE1;INSIG1;NOTCH2;ATRX;CELF2
8,prerank,KEGG_2021_Human__PI3K-Akt signaling pathway,-0.6674356964978975,-1.4152746576372552,0.002061855670103093,0.3757303622902937,0.851,12/110,6.19%,HSP90AB1;RAC1;ATF4;GRB2;YWHAZ;IL2RG;YWHAQ;PTEN;IL6R;PIK3AP1;HSP90AA1;YWHAE
9,prerank,KEGG_2021_Human__Prostate cancer,-0.7141958016820678,-1.4038577762794837,0.01639344262295082,0.3964507866813026,0.89,8/42,12.94%,HSP90AB1;ATF4;GRB2;PTEN;HSP90AA1;CREB5;EP300;GSK3B
10,prerank,KEGG_2021_Human__Thyroid hormone synthesis,-0.7980436254373593,-1.3990860842709811,0.027777777777777776,0.38316739003467604,0.908,5/17,11.67%,ATF4;PRKCB;CREB5;GNAQ;ATP1A1
11,prerank,KEGG_2021_Human__MicroRNAs in cancer,-0.6799983201624858,-1.3934240305472512,0.024096385542168676,0.3775512480701097,0.924,9/63,11.50%,PIM1;ROCK1;GRB2;PTEN;MARCKS;NOTCH2;PRKCB;EP300;NOTCH1
12,prerank,KEGG_2021_Human__Th17 cell differentiation,-0.7051947037962493,-1.3911778148020115,0.01925254813137033,0.3538569005089312,0.926,7/44,9.79%,HSP90AB1;IL2RG;TGFBR2;IL6R;HSP90AA1;PPP3CA;PPP3R1
13,prerank,MSigDB_Hallmark_2020__Protein Secretion,-0.6830712264403327,-1.3874019479462234,0.017640573318632856,0.3439276503083362,0.935,14/61,15.52%,RAB2A;VPS4B;VAMP3;AP2M1;IGF2R;CLTC;ARFIP1;GOSR2;ADAM10;ATP1A1;YKT6;ARF1;SNAP23;GLA
14,prerank,KEGG_2021_Human__Basal transcription factors,0.6508237154581453,1.3678298338902115,0.1073170731707317,1.0,0.788,2/17,4.88%,TAF7;TAF9
15,prerank,MSigDB_Hallmark_2020__Adipogenesis,0.4705455942914661,1.3653614235637892,0.0,0.97905393080805,0.793,14/95,10.61%,COX8A;ATP5PO;UQCRQ;COX6A1;CD302;UQCR10;SCP2;STOM;SLC66A3;POR;UQCRC1;COX7B;CYC1;LPCAT3
16,prerank,MSigDB_Hallmark_2020__Unfolded Protein Response,-0.6681656677569427,-1.3620155954936315,0.02826086956521739,0.46528703106840236,0.983,9/61,15.69%,IFIT1;ATF4;YWHAZ;TUBB2A;FUS;GOSR2;WIPI1;BANF1;EIF4A1
17,prerank,KEGG_2021_Human__Bacterial invasion of epithelial cells,-0.6957058253674846,-1.358469908345682,0.03274853801169591,0.45277266752595385,0.984,8/39,15.07%,ARPC2;RAC1;ELMO1;CLTC;CBL;VCL;SRC;ACTR3
18,prerank,KEGG_2021_Human__Pancreatic secretion,-0.7345273893674737,-1.356305325327255,0.06060606060606061,0.436711199164681,0.989,5/22,11.67%,RAC1;RAP1A;PRKCB;GNAQ;ATP1A1
19,prerank,KEGG_2021_Human__Chemokine signaling pathway,-0.6413842642865448,-1.3551244061654586,0.021208907741251327,0.4157898494462442,0.989,14/88,14.07%,RAC1;RAP1A;ROCK1;GRB2;WAS;CXCL2;PTK2B;ELMO1;PRKCB;DOCK2;GNAQ;HCK;GSK3B;SRC
20,prerank,KEGG_2021_Human__Aldosterone synthesis and secretion,-0.7476696541883417,-1.3534902149825039,0.05012531328320802,0.40105286311467103,0.989,7/22,11.67%,ATF4;CALM1;PRKCB;CALM2;CREB5;GNAQ;ATP1A1
21,prerank,KEGG_2021_Human__Ubiquitin mediated proteolysis,-0.6539924055418899,-1.352967523382742,0.021574973031283712,0.3813604574025982,0.989,14/71,17.27%,UBA52;UBE2D2;UBE2R2;UBE2D3;UBE2W;UBE3A;UBE2K;CBL;UBE2N;COP1;AIRE;RBX1;ANAPC11;FZR1
22,prerank,KEGG_2021_Human__Cushing syndrome,-0.6899722280612526,-1.35196593978507,0.03051643192488263,0.36711833263112803,0.99,6/39,12.94%,ATF4;RAP1A;FH;CREB5;GNAQ;GSK3B
23,prerank,KEGG_2021_Human__Thermogenesis,0.437811596781895,1.3471306831718428,0.04878048780487805,0.876269228430717,0.827,22/123,4.42%,COX8A;ATP5PF;COX4I1;ATP5PO;COX7C;COX6B1;UQCRHL;ATP5MC3;COX17;ATP5MF;COX6C;ATP5PD;ATP5F1B;UQCRQ;COX6A1;ATP5F1A;UQCRB;COX14;COX5A;RPS6KA1;COX7A2L;UQCR10
24,prerank,MSigDB_Hallmark_2020__PI3K/AKT/mTOR  Signaling,-0.6572416809536078,-1.340482512722892,0.03594771241830065,0.4064279849713975,0.996,14/60,15.42%,RAC1;GRB2;IL2RG;PTEN;UBE2D3;MKNK2;AP2M1;CLTC;PRKCB;RALB;UBE2N;GSK3B;ACTR3;ARF1
25,prerank,"KEGG_2021_Human__Growth hormone synthesis, secretion and action",-0.6725543945043773,-1.3369309420639426,0.0489749430523918,0.4060365991773451,0.996,7/45,12.94%,ATF4;GRB2;PRKCB;CREB5;EP300;GNAQ;GSK3B
26,prerank,KEGG_2021_Human__Cell cycle,-0.6878990595251747,-1.3332189033472324,0.040955631399317405,0.40723910681877,0.997,11/40,17.94%,YWHAZ;YWHAQ;STAG2;YWHAE;EP300;GSK3B;PCNA;RBX1;ANAPC11;FZR1;YWHAB
27,prerank,KEGG_2021_Human__Pancreatic cancer,-0.6705640566249035,-1.3310749137817655,0.05619266055045872,0.3997758824531404,0.997,3/46,10.13%,RAC1;TGFBR2;RALB
28,prerank,KEGG_2021_Human__Neutrophil extracellular trap formation,0.4746054232818826,1.3310473935489655,0.04395604395604396,0.8059220526539793,0.848,16/60,12.13%,CYBA;H2AJ;SIGLEC9;H3-3B;H3-3A;CYBB;ITGAM;MACROH2A1;H2AX;CAMP;SELPLG;SLC25A5;H2AW;FPR2;CASP1;TLR4
29,prerank,KEGG_2021_Human__Oxidative phosphorylation,0.453840984850434,1.3259584359393155,0.0392156862745098,0.7118970893519444,0.857,21/94,4.42%,COX8A;ATP5PF;COX4I1;ATP6V0E1;ATP5PO;COX7C;COX6B1;UQCRHL;ATP5MC3;COX17;ATP5MF;COX6C;ATP5PD;ATP5F1B;UQCRQ;COX6A1;ATP5F1A;UQCRB;COX5A;COX7A2L;UQCR10
30,prerank,KEGG_2021_Human__Estrogen signaling pathway,-0.6491615637339592,-1.3199514550711589,0.047244094488188976,0.4374730410311787,0.999,8/51,11.19%,HSP90AB1;ATF4;GRB2;HSP90AA1;CALM1;CALM2;CREB5;GNAQ
31,prerank,KEGG_2021_Human__Renal cell carcinoma,-0.6589154250332032,-1.3170445450435755,0.08032596041909197,0.4339685684452893,1.0,5/44,10.52%,RAC1;RAP1A;GRB2;FH;EP300
32,prerank,KEGG_2021_Human__Acute myeloid leukemia,-0.6804041782063173,-1.3159047579069698,0.06872037914691943,0.4234308078114134,1.0,3/39,2.38%,PIM1;FCGR1A;GRB2
33,prerank,KEGG_2021_Human__Viral carcinogenesis,-0.630227110604463,-1.3155570991904715,0.03590285110876452,0.4092458231570973,1.0,11/88,14.54%,RAC1;ATF4;GRB2;YWHAZ;YWHAQ;YWHAE;UBE3A;CREB5;EP300;SRC;IRF9
34,prerank,KEGG_2021_Human__GnRH signaling pathway,-0.6890406193438194,-1.3153074297737626,0.09723889555822329,0.3958542896155008,1.0,8/30,14.07%,ATF4;GRB2;PTK2B;CALM1;PRKCB;CALM2;GNAQ;SRC
35,prerank,KEGG_2021_Human__Colorectal cancer,-0.6553803386819648,-1.31364531763968,0.07303370786516854,0.38987308038037416,1.0,5/48,12.94%,RAC1;GRB2;TGFBR2;RALB;GSK3B
36,prerank,KEGG_2021_Human__Long-term potentiation,-0.7091734871120543,-1.3093382494808061,0.09147869674185463,0.3958940560865542,1.0,9/26,11.19%,ATF4;RAP1A;CALM1;PPP3CA;PRKCB;CALM2;PPP3R1;EP300;GNAQ
37,prerank,KEGG_2021_Human__Sphingolipid signaling pathway,-0.6431136602685879,-1.308189362268574,0.059734513274336286,0.38808564956156977,1.0,9/62,14.59%,RAC1;ROCK1;PTEN;SGPL1;ASAH1;PRKCB;GNAQ;FCER1G;PPP2R5E
38,prerank,KEGG_2021_Human__Systemic lupus erythematosus,0.5623190247810785,1.3070274192495226,0.11822660098522167,0.697239618167447,0.878,7/23,5.92%,H2AJ;H3-3B;H3-3A;HLA-DQA2;MACROH2A1;H2AX;HLA-DRA
39,prerank,KEGG_2021_Human__AGE-RAGE signaling pathway in diabetic complications,-0.6575945484921595,-1.3058292318325968,0.05862068965517241,0.38612196906820884,1.0,4/46,8.46%,RAC1;PIM1;TGFBR2;PRKCB
40,prerank,KEGG_2021_Human__Wnt signaling pathway,-0.6650610921480229,-1.3038837397174787,0.08083140877598152,0.3835314403438416,1.0,9/41,18.00%,RAC1;PPP3CA;PRKCB;PPP3R1;EP300;GSK3B;SENP2;RBX1;ROCK2
41,prerank,KEGG_2021_Human__Neurotrophin signaling pathway,-0.6397410612589354,-1.303393101972419,0.053452115812917596,0.37424188973600203,1.0,7/57,8.84%,RAC1;ATF4;RAP1A;GRB2;CALM1;YWHAE;CALM2
42,prerank,KEGG_2021_Human__TGF-beta signaling pathway,-0.6810880085718117,-1.295085077846843,0.0979689366786141,0.3988870062763667,1.0,4/31,10.52%,ROCK1;TGFBR2;ID2;EP300
43,prerank,KEGG_2021_Human__Natural killer cell mediated cytotoxicity,-0.6447463825295727,-1.2904161634629516,0.07037457434733257,0.4082691028154336,1.0,13/51,18.09%,RAC1;CD244;GRB2;PTK2B;PPP3CA;SH2D1B;PRKCB;PPP3R1;CD48;FCER1G;IFNGR2;HRAS;PAK1
44,prerank,KEGG_2021_Human__Proteoglycans in cancer,-0.6179848482430484,-1.283046533186348,0.05876068376068376,0.43213539635322185,1.0,7/77,9.04%,RAC1;IQGAP1;ROCK1;GRB2;PPP1R12A;PRKCB;CBL
45,prerank,MSigDB_Hallmark_2020__IL-2/STAT5 Signaling,-0.6067511723036907,-1.281563754575765,0.0454065469904963,0.4279114629496287,1.0,19/84,17.67%,PIM1;GLIPR2;CAPG;ANXA4;LTB;IGF2R;ST3GAL4;SLC2A3;SWAP70;PRAF2;TNFRSF1B;IFITM3;CD48;SELL;HOPX;GPX4;DCPS;IL1RL1;NDRG1
46,prerank,KEGG_2021_Human__Endocytosis,-0.5951681982648678,-1.2745203451790252,0.038894575230296824,0.4468946357115348,1.0,19/128,10.17%,ARPC2;SNX3;CAPZA1;RAB11FIP1;CHMP4B;IL2RG;EHD4;VPS4B;CHMP2B;TGFBR2;AP2M1;SH3GL1;RAB31;IGF2R;PIP5K1B;CLTC;CBL;CHMP1A;BIN1
47,prerank,KEGG_2021_Human__Epithelial cell signaling in Helicobacter pylori infection,-0.6533328832554599,-1.2693100767336754,0.11560693641618497,0.4592368120443005,1.0,4/38,3.48%,RAC1;ATP6V0C;CXCL2;ATP6V1E1
48,prerank,KEGG_2021_Human__Retrograde endocannabinoid signaling,-0.624507031753554,-1.2658541864740562,0.08881578947368421,0.4628939746065287,1.0,14/59,18.50%,ND4;ND1;NDUFS7;NDUFB1;NDUFA1;ND5;PRKCB;NDUFA12;GNAQ;NDUFB9;NDUFA2;NDUFS8;NDUFA5;NDUFA4
49,prerank,KEGG_2021_Human__Calcium signaling pathway,-0.6641199378321718,-1.2657141343440763,0.11377245508982035,0.452521510866669,1.0,9/32,11.71%,PTK2B;CALM1;PPP3CA;PRKCB;CALM2;ORAI2;PPP3R1;GNAQ;TNNC2
50,prerank,KEGG_2021_Human__Hippo signaling pathway,-0.6306682900185573,-1.260436141516783,0.10224719101123596,0.4644645941009228,1.0,7/46,12.94%,YWHAZ;YWHAQ;TGFBR2;YWHAE;MOB1A;ID2;GSK3B
51,prerank,KEGG_2021_Human__Ras signaling pathway,-0.6114071177899194,-1.2560382966593848,0.08512931034482758,0.4740467781885683,1.0,8/73,10.13%,RAC1;RAP1A;GRB2;CALM1;RASGRP4;PRKCB;CALM2;RALB
52,prerank,KEGG_2021_Human__Fc gamma R-mediated phagocytosis,-0.6214631997162514,-1.2548844903317387,0.10572687224669604,0.46845461026875185,1.0,9/52,11.42%,ARPC2;RAC1;FCGR1A;WAS;MARCKS;PIP5K1B;PRKCB;BIN1;HCK
53,prerank,KEGG_2021_Human__Choline metabolism in cancer,-0.6341473331748585,-1.2533664351108913,0.14719626168224298,0.4652649813616926,1.0,5/42,8.46%,RAC1;GRB2;WAS;PIP5K1B;PRKCB
54,prerank,KEGG_2021_Human__Pathways in cancer,-0.5859668381131596,-1.2520058876780147,0.02131979695431472,0.46097667308270346,1.0,23/184,11.50%,HSP90AB1;RAC1;PIM1;ROCK1;GRB2;IL2RG;PTEN;TGFBR2;IL6R;HSP90AA1;NOTCH2;CALM1;CASP7;RASGRP4;PRKCB;CALM2;NFE2L2;CBL;FH;RALB;EP300;GNAQ;NOTCH1
55,prerank,KEGG_2021_Human__Diabetic cardiomyopathy,0.39451577684903266,1.2501293886666536,0.0,0.8463549583510671,0.933,20/120,4.42%,CYBA;COX8A;ATP5PF;COX4I1;ATP5PO;COX7C;COX6B1;UQCRHL;ATP5MC3;COX6C;ATP5PD;ATP5F1B;UQCRQ;COX6A1;ATP5F1A;UQCRB;CYBB;COX5A;COX7A2L;UQCR10
56,prerank,KEGG_2021_Human__Vascular smooth muscle contraction,-0.6562648785415879,-1.240504466359151,0.16403402187120292,0.5028522589012937,1.0,7/30,15.05%,ROCK1;PPP1R12A;CALM1;PRKCB;CALM2;GNAQ;MYH11
57,prerank,KEGG_2021_Human__Human cytomegalovirus infection,-0.5835278690929442,-1.2390240089185949,0.07507820646506778,0.4986356674875246,1.0,15/113,14.07%,RAC1;ATF4;ROCK1;GRB2;PTK2B;IL6R;CALM1;PPP3CA;PRKCB;CALM2;CREB5;PPP3R1;GNAQ;GSK3B;SRC
58,prerank,KEGG_2021_Human__MAPK signaling pathway,-0.5889375874771944,-1.2382137460120415,0.06749740394600208,0.4917044612817149,1.0,10/105,9.79%,RAC1;ATF4;RAP1A;GRB2;TGFBR2;MKNK2;RASGRP4;PPP3CA;PRKCB;PPP3R1
59,prerank,KEGG_2021_Human__Dopaminergic synapse,-0.6319078646961084,-1.2376054367228586,0.1334867663981588,0.48464863353353627,1.0,10/45,14.59%,ATF4;CALM1;PPP3CA;PRKCB;COMT;CALM2;CREB5;GNAQ;GSK3B;PPP2R5E
60,prerank,MSigDB_Hallmark_2020__Mitotic Spindle,-0.5919696560980712,-1.2352176490241404,0.09774436090225563,0.4847444272593532,1.0,12/79,14.17%,ROCK1;SSH2;MARCKS;NOTCH2;YWHAE;DOCK2;PCGF5;KNTC1;BIN1;VCL;RAB3GAP1;RFC1
61,prerank,KEGG_2021_Human__Progesterone-mediated oocyte maturation,-0.6458995225851724,-1.2320160785843508,0.17611580217129072,0.48894988877399503,1.0,3/30,5.67%,HSP90AB1;STK10;HSP90AA1
62,prerank,KEGG_2021_Human__Renin secretion,-0.6907418412850433,-1.229242974992283,0.20178799489144317,0.4914856759251822,1.0,5/18,11.19%,CALM1;PPP3CA;CALM2;PPP3R1;GNAQ
63,prerank,KEGG_2021_Human__Cell adhesion molecules,0.5605470162051234,1.2217632962308005,0.1859504132231405,0.8877606858393629,0.955,5/20,13.36%,ITGAM;HLA-DQA2;HLA-DRA;SELPLG;CLDN1
64,prerank,KEGG_2021_Human__Prion disease,0.39403655661162773,1.2142886041149241,0.0,0.8380638635396344,0.96,24/170,4.42%,CYBA;COX8A;ATP5PF;TUBA1B;COX4I1;ATP5PO;COX7C;COX6B1;UQCRHL;ATP5MC3;COX6C;ATP5PD;ATP5F1B;UQCRQ;COX6A1;ATP5F1A;UQCRB;CYBB;SEM1;COX5A;TUBA1A;COX7A2L;TUBB;UQCR10
65,prerank,KEGG_2021_Human__Breast cancer,-0.60661435033971,-1.21342672641314,0.15953757225433526,0.5508116694778364,1.0,10/47,21.67%,GRB2;PTEN;NOTCH2;NOTCH1;GSK3B;HRAS;FRAT1;AKT2;HES1;AKT1
66,prerank,KEGG_2021_Human__VEGF signaling pathway,-0.635151548122602,-1.2130335803165262,0.18453865336658354,0.5428437244620211,1.0,5/30,14.07%,RAC1;PPP3CA;PRKCB;PPP3R1;SRC
67,prerank,KEGG_2021_Human__JAK-STAT signaling pathway,-0.6022620255210952,-1.2113588028758484,0.15532879818594103,0.5405684434104726,1.0,10/50,19.17%,PIM1;GRB2;IL2RG;IL6R;EP300;IL12A;IRF9;IFNGR2;HRAS;IL10RB
68,prerank,MSigDB_Hallmark_2020__Complement,-0.5766328996124276,-1.207991280237617,0.12108559498956159,0.5460254030035664,1.0,8/92,6.92%,TIMP2;PIM1;GRB2;WAS;LTF;CTSH;CALM1;CASP7
69,prerank,KEGG_2021_Human__Oxytocin signaling pathway,-0.6048957144783206,-1.2071215042724055,0.16704545454545455,0.5406147091108672,1.0,12/51,18.53%,ROCK1;PPP1R12A;CALM1;PPP3CA;PRKCB;CALM2;PPP3R1;GNAQ;SRC;ROCK2;HRAS;KCNJ2
70,prerank,KEGG_2021_Human__Glutamatergic synapse,-0.6569812568099664,-1.200919169448808,0.1925,0.5583568341171885,1.0,5/24,11.19%,PPP3CA;PRKCB;PPP3R1;GLUL;GNAQ
71,prerank,KEGG_2021_Human__Hepatitis C,-0.5758530146709081,-1.200352553303084,0.13752665245202558,0.5518549989444398,1.0,5/82,6.19%,IFIT1;GRB2;YWHAZ;YWHAQ;YWHAE
72,prerank,KEGG_2021_Human__Oocyte meiosis,-0.610250429408898,-1.1993981467922776,0.19204545454545455,0.5473351752036694,1.0,11/42,17.94%,YWHAZ;YWHAQ;CALM1;YWHAE;PPP3CA;CALM2;PPP3R1;PPP2R5E;RBX1;ANAPC11;YWHAB
73,prerank,KEGG_2021_Human__Hepatocellular carcinoma,-0.5818741244727368,-1.198392206220797,0.17081081081081081,0.5427914001580034,1.0,15/68,21.67%,GRB2;PTEN;TGFBR2;PRKCB;NFE2L2;GSK3B;MGST3;TXNRD1;HRAS;TXNRD2;FRAT1;AKT2;GSTP1;PBRM1;AKT1
74,prerank,KEGG_2021_Human__Purine metabolism,0.4930089020674707,1.1972705498194829,0.16326530612244897,0.8361707302243571,0.967,12/31,17.05%,PNP;NT5E;ADSS2;NT5C;IMPDH1;NT5C3A;NUDT16;PKM;ADA;ADPRM;NME6;CANT1
75,prerank,KEGG_2021_Human__Glioma,-0.6225141921270256,-1.1970730882580507,0.21670702179176757,0.5399828931398535,1.0,5/34,8.84%,GRB2;PTEN;CALM1;PRKCB;CALM2
76,prerank,KEGG_2021_Human__Synaptic vesicle cycle,-0.6516128358500938,-1.1885972936022475,0.23943661971830985,0.5674459682197093,1.0,5/22,8.94%,ATP6V0C;ATP6V1E1;AP2M1;CLTC;VAMP2
77,prerank,KEGG_2021_Human__Leishmaniasis,0.4574623506215538,1.1863155568290424,0.20149253731343283,0.8164687504384712,0.969,8/42,9.52%,CYBA;CYBB;ITGAM;HLA-DQA2;TAB2;HLA-DRA;PTGS2;IRAK1
78,prerank,KEGG_2021_Human__Glycolysis / Gluconeogenesis,0.5120304771994582,1.1847713028848024,0.20465116279069767,0.763361099288624,0.969,5/23,11.46%,LDHA;GPI;LDHC;PKM;PGAM4
79,prerank,KEGG_2021_Human__Human T-cell leukemia virus 1 infection,-0.5600713704127148,-1.1816113588275383,0.16422594142259414,0.5881765501119736,1.0,8/95,10.52%,ATF4;IL2RG;PTEN;TGFBR2;PPP3CA;CREB5;PPP3R1;EP300
80,prerank,KEGG_2021_Human__Yersinia infection,-0.5688805996164316,-1.1777433442748007,0.15508021390374332,0.59541746702753,1.0,12/80,15.07%,ARPC2;RAC1;ROCK1;WAS;PTK2B;ELMO1;SKAP2;PIP5K1B;GNAQ;GSK3B;SRC;ACTR3
81,prerank,KEGG_2021_Human__cGMP-PKG signaling pathway,-0.5882303835800871,-1.17495644158753,0.20446927374301677,0.5984767712337806,1.0,10/52,11.67%,ATF4;ROCK1;PPP1R12A;CALM1;PPP3CA;CALM2;CREB5;PPP3R1;GNAQ;ATP1A1
82,prerank,KEGG_2021_Human__Chemical carcinogenesis,-0.5654498283623797,-1.1704248486194975,0.18102508178844057,0.6095117126897895,1.0,8/70,9.31%,HSP90AB1;ATF4;GRB2;HSP90AA1;NOTCH2;PTGES3;PRKCB;CREB5
83,prerank,MSigDB_Hallmark_2020__IL-6/JAK/STAT3 Signaling,-0.5769510944695393,-1.170027847321584,0.21612541993281076,0.60258761478943,1.0,8/51,14.54%,PIM1;GRB2;IL2RG;LTB;CBL;TNFRSF1B;CD9;IRF9
84,prerank,KEGG_2021_Human__Hepatitis B,-0.559978943829865,-1.170013661439052,0.2035490605427975,0.594174751057818,1.0,11/86,14.07%,ATF4;GRB2;YWHAZ;YWHAQ;PTK2B;TGFBR2;PRKCB;CREB5;EP300;PCNA;SRC
85,prerank,KEGG_2021_Human__Inositol phosphate metabolism,-0.6188914405886713,-1.1691113064272396,0.24428399518652227,0.5895239802196779,1.0,6/31,17.21%,PTEN;PIP4K2A;PIP5K1B;SACM1L;SYNJ1;PI4K2A
86,prerank,KEGG_2021_Human__Notch signaling pathway,-0.6375946986878251,-1.1690439086738311,0.24727272727272728,0.5817373114410511,1.0,5/25,15.32%,NOTCH2;EP300;NOTCH1;CIR1;PSENEN
87,prerank,KEGG_2021_Human__Proteasome,0.4519132729903687,1.166562256954412,0.16666666666666666,0.782148720131331,0.977,2/42,2.44%,POMP;SEM1
88,prerank,KEGG_2021_Human__Ribosome,-0.5453087292528134,-1.1634566165633493,0.17671517671517672,0.595757171859552,1.0,13/109,18.07%,UBA52;RPL7A;RPL13A;RPL39;RPL5;RPLP1;RPL37A;MRPL30;MRPL3;RPS8;MRPL16;RPS15;MRPL10
89,prerank,KEGG_2021_Human__Adrenergic signaling in cardiomyocytes,-0.5834627974931619,-1.1620440410245645,0.25223214285714285,0.5939201984775062,1.0,7/47,14.59%,ATF4;CALM1;CALM2;CREB5;GNAQ;ATP1A1;PPP2R5E
90,prerank,KEGG_2021_Human__Cholinergic synapse,-0.6022554027237499,-1.1509646124877961,0.27283653846153844,0.6298034130465517,1.0,9/34,21.67%,ATF4;PRKCB;CREB5;GNAQ;HRAS;KCNJ2;GNGT2;AKT2;AKT1
91,prerank,KEGG_2021_Human__Melanogenesis,-0.6281944913191828,-1.1494530207826006,0.2716049382716049,0.6273208376231053,1.0,6/25,12.94%,CALM1;PRKCB;CALM2;EP300;GNAQ;GSK3B
92,prerank,KEGG_2021_Human__Phosphatidylinositol signaling system,-0.5915403895681233,-1.1483415880646604,0.25,0.6237411234198469,1.0,9/39,17.21%,PTEN;CALM1;PIP4K2A;PIP5K1B;PRKCB;CALM2;SACM1L;SYNJ1;PI4K2A
93,prerank,KEGG_2021_Human__ErbB signaling pathway,-0.5989766867629107,-1.1470713361432774,0.2757352941176471,0.6212534823315413,1.0,10/33,21.67%,GRB2;PRKCB;CBL;GSK3B;SRC;HRAS;PAK1;AKT2;CDKN1B;AKT1
94,prerank,KEGG_2021_Human__Pyrimidine metabolism,0.5443636826632238,1.145770212743429,0.2893772893772894,0.8106721590563628,0.986,7/15,17.05%,PNP;NT5E;NT5C;NT5C3A;NME6;TK1;CANT1
95,prerank,KEGG_2021_Human__Toxoplasmosis,0.42008018155402954,1.1399016757519946,0.1792452830188679,0.7862689065411536,0.988,9/50,14.40%,HLA-DQA2;IRGM;TAB2;BIRC3;HLA-DRA;CYCS;IRAK1;TLR4;MAPK13
96,prerank,KEGG_2021_Human__Fc epsilon RI signaling pathway,-0.5941381927339312,-1.1396436167232171,0.2717258261933905,0.6437490517879932,1.0,2/32,2.38%,RAC1;GRB2
97,prerank,KEGG_2021_Human__Viral protein interaction with cytokine and cytokine receptor,-0.5907587130578749,-1.1318762907604987,0.29865361077111385,0.6658628142568777,1.0,5/29,10.59%,IL2RG;CXCL2;IL6R;TNFRSF1B;TNFRSF14
98,prerank,MSigDB_Hallmark_2020__Coagulation,-0.5813812118785514,-1.1317549205791062,0.27842227378190254,0.65827854109978,1.0,5/39,13.57%,RAC1;CTSH;PEF1;CD9;KLF7
99,prerank,KEGG_2021_Human__Coronavirus disease,-0.5244484619460682,-1.1314109056783872,0.22391084093211752,0.6516395694421282,1.0,9/140,8.46%,UBA52;RPL7A;RPL13A;RPL39;C4A;IL6R;RPL5;RPLP1;PRKCB
100,prerank,"KEGG_2021_Human__Parathyroid hormone synthesis, secretion and action",-0.5722213549933073,-1.1212488421275701,0.29058823529411765,0.68418213447463,1.0,5/41,11.19%,ATF4;MMP25;PRKCB;CREB5;GNAQ
101,prerank,KEGG_2021_Human__Viral myocarditis,-0.6350533339988267,-1.1209609769631155,0.34908136482939633,0.6772291578407487,1.0,2/17,4.38%,RAC1;EIF4G2
102,prerank,KEGG_2021_Human__Fluid shear stress and atherosclerosis,-0.543056235332717,-1.1143569476430932,0.29,0.6945401563504313,1.0,8/62,8.86%,HSP90AB1;RAC1;SUMO1;TXN;HSP90AA1;CALM1;CALM2;NFE2L2
103,prerank,KEGG_2021_Human__Leukocyte transendothelial migration,0.40984274807006155,1.1134000847281165,0.20353982300884957,0.8484830060193349,0.992,6/52,3.44%,CYBA;VASP;MYL12B;MYL12A;CYBB;ITGAM
104,prerank,KEGG_2021_Human__Endometrial cancer,-0.5796817962062129,-1.1127993013401483,0.3238566131025958,0.6924677782301499,1.0,7/32,22.73%,GRB2;PTEN;GSK3B;HRAS;AKT2;AKT1;FOXO3
105,prerank,KEGG_2021_Human__Gastric acid secretion,-0.6357566598378708,-1.1120437324658756,0.34856396866840733,0.6875556250572984,1.0,5/17,11.67%,CALM1;PRKCB;CALM2;GNAQ;ATP1A1
106,prerank,KEGG_2021_Human__Chronic myeloid leukemia,-0.5588063875376086,-1.1094752905044936,0.30549199084668194,0.689825751598085,1.0,3/45,9.04%,GRB2;TGFBR2;CBL
107,prerank,MSigDB_Hallmark_2020__Epithelial Mesenchymal Transition,-0.564308475120751,-1.1079919606312036,0.31746031746031744,0.6876501893449232,1.0,6/40,14.84%,SAT1;CAPG;NOTCH2;ID2;COLGALT1;SERPINE2
108,prerank,KEGG_2021_Human__Platelet activation,0.4069720423687239,1.1057446210422723,0.234375,0.8343546895450459,0.992,4/50,0.56%,VASP;MYL12B;APBB1IP;MYL12A
109,prerank,KEGG_2021_Human__Relaxin signaling pathway,-0.5534380772251096,-1.1023010611174209,0.3210161662817552,0.7009782360643114,1.0,4/49,9.31%,ATF4;GRB2;TGFBR2;CREB5
110,prerank,KEGG_2021_Human__Regulation of actin cytoskeleton,-0.5266253614131854,-1.1020129311946925,0.29123173277661796,0.6941806264814903,1.0,14/88,15.07%,ARPC2;RAC1;IQGAP1;ROCK1;PPP1R12A;SSH2;IQGAP2;PIP4K2A;PIP5K1B;SSH1;VCL;SRC;MYH11;ACTR3
111,prerank,KEGG_2021_Human__Phagosome,0.37839527992331573,1.1014657502000866,0.19117647058823528,0.8060436553778805,0.992,11/76,4.27%,CYBA;TUBA1B;ATP6V0E1;RAB7A;FCAR;CYBB;TUBA1A;CTSS;ITGAM;HLA-DQA2;TUBB
112,prerank,KEGG_2021_Human__B cell receptor signaling pathway,-0.547663770410911,-1.1003594303818232,0.32389580973952437,0.692831848292988,1.0,7/50,12.94%,RAC1;GRB2;PIK3AP1;PPP3CA;PRKCB;PPP3R1;GSK3B
113,prerank,KEGG_2021_Human__Huntington disease,0.37219883356099737,1.0972104704466616,0.09090909090909091,0.7840769918960472,0.993,22/178,4.42%,COX8A;ATP5PF;TUBA1B;COX4I1;ATP5PO;COX7C;COX6B1;UQCRHL;ATP5MC3;COX6C;ATP5PD;ATP5F1B;UQCRQ;COX6A1;ATP5F1A;UQCRB;SEM1;COX5A;TUBA1A;COX7A2L;TUBB;UQCR10
114,prerank,KEGG_2021_Human__Inflammatory mediator regulation of TRP channels,-0.5881532727567891,-1.095001180399484,0.3549618320610687,0.7055484856994914,1.0,5/25,14.07%,CALM1;PRKCB;CALM2;GNAQ;SRC
115,prerank,KEGG_2021_Human__Alzheimer disease,0.34668365799774903,1.0947782997236768,0.0,0.7574744219725067,0.993,24/208,4.42%,COX8A;ATP5PF;TUBA1B;COX4I1;ATP5PO;COX7C;COX6B1;UQCRHL;ATP5MC3;COX6C;ATP5PD;ATP5F1B;UQCRQ;COX6A1;ATP5F1A;UQCRB;CYBB;SEM1;COX5A;TUBA1A;CALM3;COX7A2L;TUBB;UQCR10
116,prerank,KEGG_2021_Human__Gastric cancer,-0.5520897214063996,-1.0925934147741179,0.3701149425287356,0.7070416865703119,1.0,8/45,21.67%,GRB2;TGFBR2;GSK3B;HRAS;FRAT1;AKT2;CDKN1B;AKT1
117,prerank,KEGG_2021_Human__Cellular senescence,-0.5254868402447166,-1.0903104553260465,0.3402625820568928,0.707752925327003,1.0,7/66,9.79%,PTEN;TGFBR2;CALM1;ZFP36L2;PPP3CA;CALM2;PPP3R1
118,prerank,KEGG_2021_Human__Th1 and Th2 cell differentiation,-0.5627932252539843,-1.0877551452955152,0.37529411764705883,0.709301360613502,1.0,7/35,16.61%,IL2RG;NOTCH2;PPP3CA;PPP3R1;NOTCH1;IL12A;IFNGR2
119,prerank,KEGG_2021_Human__Phospholipase D signaling pathway,-0.5333353532566925,-1.0772978696687736,0.36961451247165533,0.7397998796852145,1.0,14/53,25.30%,GRB2;PTK2B;PIP5K1B;RALB;FCER1G;ARF1;HRAS;CYTH4;AKT2;AKT1;AGPAT1;CYTH1;MAPK3;LPAR6
120,prerank,KEGG_2021_Human__Vibrio cholerae infection,-0.5886426448059291,-1.0769424644283039,0.3826530612244898,0.7335524936927844,1.0,5/23,15.42%,ATP6V0C;ATP6V1E1;SEC61B;SEC61G;ARF1
121,prerank,KEGG_2021_Human__Rheumatoid arthritis,-0.5432398663363637,-1.0748687176878209,0.3786635404454865,0.7335833935726843,1.0,4/39,7.56%,ATP6V0C;CXCL2;ATP6V1E1;LTB
122,prerank,KEGG_2021_Human__Signaling pathways regulating pluripotency of stem cells,-0.5396415693250194,-1.0748422874087233,0.3786848072562358,0.7263898192448358,1.0,4/43,12.94%,GRB2;PCGF5;ID2;GSK3B
123,prerank,KEGG_2021_Human__T cell receptor signaling pathway,-0.5319966521473034,-1.06747881088246,0.3779527559055118,0.7432267258683435,1.0,7/50,18.09%,GRB2;TEC;PPP3CA;PPP3R1;GSK3B;HRAS;PAK1
124,prerank,KEGG_2021_Human__Parkinson disease,0.36470118152045417,1.0618796758177032,0.2727272727272727,0.8451653664868178,0.997,23/161,4.42%,COX8A;ATP5PF;TUBA1B;COX4I1;ATP5PO;COX7C;COX6B1;UQCRHL;ATP5MC3;COX6C;ATP5PD;ATP5F1B;UQCRQ;COX6A1;ATP5F1A;UQCRB;SEM1;COX5A;TUBA1A;CALM3;COX7A2L;TUBB;UQCR10
125,prerank,KEGG_2021_Human__PPAR signaling pathway,0.49323273420998254,1.060934464944649,0.3574660633484163,0.8138262297075455,0.997,9/20,18.59%,SCP2;ACAA1;SCD;FABP5;SLC27A4;ACSL5;DBI;PLIN2;ACADL
126,prerank,MSigDB_Hallmark_2020__Androgen Response,-0.5346517349136563,-1.0517348310366028,0.4085155350978136,0.7899657227045558,1.0,5/43,6.29%,SAT1;PTK2B;INSIG1;IQGAP2;SELENOP
127,prerank,MSigDB_Hallmark_2020__Apoptosis,-0.5006459189214245,-1.0442157981227287,0.4167539267015707,0.8075918229628973,1.0,9/82,11.36%,TIMP2;SAT1;ROCK1;DNAJA1;ETF1;CASP7;IGF2R;PPP3R1;IFITM3
128,prerank,KEGG_2021_Human__AMPK signaling pathway,-0.5115078599269869,-1.032649219074376,0.4420697412823397,0.8397590340965351,1.0,14/50,23.65%,RAB2A;CREB5;PPP2R5E;ADIPOR1;HMGCR;SREBF1;RAB10;RAB8A;AKT2;AKT1;CAB39L;EEF2;FOXO3;PFKFB3
129,prerank,KEGG_2021_Human__Cytokine-cytokine receptor interaction,-0.5016372097817433,-1.0323663210417902,0.4370860927152318,0.8328153422681215,1.0,14/61,19.53%,IL2RG;CXCL2;TGFBR2;IL6R;LTB;TNFRSF1B;TNFRSF14;IL12A;IFNGR2;IL1RL1;GDF15;TNFSF14;IL10RB;CXCL1
130,prerank,KEGG_2021_Human__TNF signaling pathway,-0.49767939953709983,-1.027770799588982,0.46630434782608693,0.8404769822291205,1.0,5/64,9.88%,ATF4;CXCL2;CASP7;CREB5;TNFRSF1B
131,prerank,KEGG_2021_Human__Lysosome,-0.4988673822413002,-1.0273450097098673,0.4525862068965517,0.8340377784190088,1.0,7/71,10.71%,CD68;ATP6V0C;CTSH;IGF2R;ASAH1;CLTC;HEXB
132,prerank,KEGG_2021_Human__Glucagon signaling pathway,-0.5304170960515945,-1.0271164193693412,0.48398576512455516,0.8271844573550017,1.0,8/35,11.19%,ATF4;CALM1;PPP3CA;CALM2;CREB5;PPP3R1;EP300;GNAQ
133,prerank,KEGG_2021_Human__Lysine degradation,-0.5614487103819331,-1.0259163803575566,0.47006369426751593,0.823748177607512,1.0,6/22,24.46%,KMT2C;COLGALT1;ALDH3A2;ECHS1;HADHA;KMT2A
134,prerank,MSigDB_Hallmark_2020__Spermatogenesis,0.46435939139603877,1.0232587156538155,0.40869565217391307,0.9282179120812306,0.997,9/20,24.80%,LDHC;CSNK2A2;AGFG1;IP6K1;ZC3H14;LPIN1;TSN;VDAC3;RAD17
135,prerank,KEGG_2021_Human__Tight junction,-0.5026246997311732,-1.0205147398816092,0.4794816414686825,0.8332902793827534,1.0,6/60,2.46%,ARPC2;RAC1;RAP1A;RAB8B;ROCK1;WAS
136,prerank,KEGG_2021_Human__Amino sugar and nucleotide sugar metabolism,0.4686459560550755,1.0186260593028376,0.417910447761194,0.9112487196636281,0.997,5/20,7.11%,GPI;CYB5R3;PMM1;CYB5R4;CHIT1
137,prerank,KEGG_2021_Human__Axon guidance,-0.5073684097053218,-1.0173441886230847,0.46559633027522934,0.83622609708926,1.0,13/47,18.09%,RAC1;ROCK1;SSH2;PPP3CA;SSH1;PPP3R1;GSK3B;SRC;SRGAP2;SEMA4B;ROCK2;HRAS;PAK1
138,prerank,KEGG_2021_Human__Prolactin signaling pathway,-0.5255709538487114,-1.015936690431569,0.474390243902439,0.833431145770226,1.0,7/34,22.73%,GRB2;GSK3B;SRC;HRAS;AKT2;AKT1;FOXO3
139,prerank,KEGG_2021_Human__Non-small cell lung cancer,-0.517213159835979,-1.012602017229743,0.4803337306317044,0.8367151916362887,1.0,2/39,8.46%,GRB2;PRKCB
140,prerank,KEGG_2021_Human__Circadian entrainment,-0.5674082097003692,-1.0076292636476893,0.49744897959183676,0.8448724380815135,1.0,4/21,11.19%,CALM1;PRKCB;CALM2;GNAQ
141,prerank,KEGG_2021_Human__Primary immunodeficiency,-0.584692806899052,-0.9991220356992218,0.517464424320828,0.8637862101585548,1.0,3/16,16.98%,IL2RG;AICDA;AIRE
142,prerank,KEGG_2021_Human__NOD-like receptor signaling pathway,0.34300181698800053,0.9975221194532898,0.4523809523809524,0.9673496686325773,0.999,10/91,5.65%,CYBA;GABARAP;TXNIP;IFI16;CYBB;GBP2;TAB2;BIRC3;PYCARD;CAMP
143,prerank,MSigDB_Hallmark_2020__G2-M Checkpoint,-0.4812888878956396,-0.9974738987869081,0.5230439442658092,0.8611668120115015,1.0,9/72,15.94%,MARCKS;NOTCH2;ATRX;EWSR1;CHMP1A;SS18;DDX39A;SQLE;SMC2
144,prerank,KEGG_2021_Human__Human papillomavirus infection,-0.4658395634349305,-0.9939943661263121,0.5211995863495347,0.8641417340795298,1.0,12/122,14.59%,ATP6V0C;GRB2;ATP6V1E1;PTEN;NOTCH2;UBE3A;CREB5;EP300;NOTCH1;GSK3B;IRF9;PPP2R5E
145,prerank,KEGG_2021_Human__Antigen processing and presentation,-0.5231044517172923,-0.9922264638499756,0.5048661800486618,0.8621395547590136,1.0,2/27,5.67%,HSP90AB1;HSP90AA1
146,prerank,KEGG_2021_Human__Focal adhesion,-0.4790435370395839,-0.9886761365259267,0.5369565217391304,0.8658845590925722,1.0,11/71,14.07%,RAC1;RAP1A;ROCK1;GRB2;PPP1R12A;PTEN;PIP5K1B;PRKCB;VCL;GSK3B;SRC
147,prerank,MSigDB_Hallmark_2020__TNF-alpha Signaling via NF-kB,-0.45759645626344186,-0.9841196187874102,0.5352400408580184,0.8721902777264566,1.0,19/124,21.21%,SAT1;CXCL2;TUBB2A;MARCKS;SLC2A3;NFE2L2;CCNL1;ID2;FOSL2;IFNGR2;CEBPD;PLEK;B4GALT5;IER5;PHLDA1;CXCL1;EIF1;JUNB;HES1
148,prerank,KEGG_2021_Human__Long-term depression,-0.5572884328805618,-0.9809215747990784,0.5506493506493506,0.8743216215160478,1.0,3/20,18.03%,PRKCB;GNAQ;HRAS
149,prerank,KEGG_2021_Human__Lipid and atherosclerosis,-0.46409534786585965,-0.9800310117957542,0.546875,0.8696860856857879,1.0,16/108,14.73%,HSP90AB1;RAC1;ATF4;RAP1A;CXCL2;HSP90AA1;CALM1;CASP7;PPP3CA;CALM2;NFE2L2;PPP3R1;GSK3B;SRC;IL12A;LY96
150,prerank,MSigDB_Hallmark_2020__Interferon Alpha Response,0.3493382164351853,0.9794697064808309,0.5526315789473685,1.0,0.999,16/80,14.77%,IFI27;TXNIP;OASL;IFI44;CD47;TRIM5;GBP2;CNP;BST2;IFIT2;CASP1;ISG20;GBP4;IFIH1;NUB1;ISG15
151,prerank,KEGG_2021_Human__Transcriptional misregulation in cancer,-0.47037360565635855,-0.968613479670281,0.5666666666666667,0.8949846026203614,1.0,10/72,12.23%,FCGR1A;LYL1;TGFBR2;FUS;EWSR1;CDK14;ID2;SS18;KDM6A;FLI1
152,prerank,MSigDB_Hallmark_2020__TGF-beta Signaling,-0.5101740777715881,-0.9680714934146419,0.5611510791366906,0.8893226241153739,1.0,6/31,21.17%,UBE2D3;RAB31;ID2;IFNGR2;JUNB;FNTA
153,prerank,MSigDB_Hallmark_2020__E2F Targets,0.3480030424655951,0.9669483886060727,0.49074074074074076,1.0,1.0,6/60,9.58%,POLE4;TUBB;H2AX;SLBP;UBE2S;TMPO
154,prerank,KEGG_2021_Human__mTOR signaling pathway,-0.4690045911547166,-0.9613520356006076,0.57,0.9014152033214441,1.0,5/65,12.94%,GRB2;ATP6V1E1;PTEN;PRKCB;GSK3B
155,prerank,MSigDB_Hallmark_2020__UV Response Up,-0.4606431984095064,-0.9587037647831514,0.5685224839400428,0.9013913621162538,1.0,4/74,6.42%,CREG1;CXCL2;DNAJA1;PDAP1
156,prerank,MSigDB_Hallmark_2020__KRAS Signaling Dn,-0.5575164560513597,-0.9580399812617166,0.5798090040927695,0.89612107384452,1.0,3/15,17.36%,SELENOP;IFI44L;BRDT
157,prerank,KEGG_2021_Human__Pathogenic Escherichia coli infection,-0.45877343695864586,-0.9569959062004251,0.5873180873180873,0.8919819019750966,1.0,7/96,6.92%,ARPC2;RAC1;ROCK1;TUBB2A;GAPDH;RAB1A;CASP7
158,prerank,KEGG_2021_Human__Thyroid hormone signaling pathway,-0.47344895373646584,-0.9523631118435953,0.5997719498289624,0.8974068933039242,1.0,7/52,14.07%,NOTCH2;PRKCB;EP300;NOTCH1;ATP1A1;GSK3B;SRC
159,prerank,MSigDB_Hallmark_2020__Glycolysis,0.34613295377669,0.9445468279236986,0.6190476190476191,1.0,1.0,9/64,12.32%,LDHA;HDLBP;NT5E;LDHC;PKM;AGL;CD44;ISG20;SRD5A3
160,prerank,KEGG_2021_Human__Kaposi sarcoma-associated herpesvirus infection,-0.4480127706114341,-0.9437714233379955,0.6231578947368421,0.91279436809585,1.0,12/103,14.54%,UBA52;RAC1;CXCL2;CALM1;PPP3CA;CALM2;PPP3R1;EP300;HCK;GSK3B;SRC;IRF9
161,prerank,KEGG_2021_Human__Staphylococcus aureus infection,0.4069900371838944,0.9435168861630936,0.4976958525345622,1.0,1.0,9/25,11.54%,FCAR;ITGAM;HLA-DQA2;CAMP;HLA-DRA;SELPLG;FCGR2B;FPR2;KRT16
162,prerank,KEGG_2021_Human__Hematopoietic cell lineage,0.40728939199332287,0.9432709566996031,0.5161290322580645,1.0,1.0,7/29,6.23%,CSF2RA;CD24;ITGAM;HLA-DQA2;ANPEP;HLA-DRA;CD55
163,prerank,KEGG_2021_Human__Apelin signaling pathway,0.3427389111665979,0.9418422528753534,0.6724137931034483,1.0,1.0,2/50,3.38%,GABARAP;CALM3
164,prerank,MSigDB_Hallmark_2020__Reactive Oxygen Species Pathway,-0.48887706906902945,-0.9405543151109235,0.5910165484633569,0.9138239912984899,1.0,7/33,20.98%,TXN;GPX4;TXNRD1;IPCEF1;TXNRD2;FTL;JUNB
165,prerank,KEGG_2021_Human__Central carbon metabolism in cancer,0.3991560107126295,0.938723260468101,0.5572139303482587,0.993458488764266,1.0,6/30,14.80%,LDHA;LDHC;PKM;PGAM4;NRAS;HK1
166,prerank,KEGG_2021_Human__Human immunodeficiency virus 1 infection,-0.4484275649291166,-0.9380942672514666,0.643305439330544,0.9128817532573368,1.0,9/101,11.19%,RAC1;PTK2B;CALM1;PPP3CA;PRKCB;CALM2;PPP3R1;TNFRSF1B;GNAQ
167,prerank,KEGG_2021_Human__GABAergic synapse,0.44120473973261765,0.9307746304930712,0.5301724137931034,0.995926308749316,1.0,1/17,0.12%,GABARAP
168,prerank,KEGG_2021_Human__Legionellosis,-0.4774132974570099,-0.9241852080420648,0.6156583629893239,0.9407784908820466,1.0,8/34,19.78%,CXCL2;RAB1A;CASP7;IL12A;ARF1;EEF1A1;CXCL1;HSPA8
169,prerank,MSigDB_Hallmark_2020__p53 Pathway,0.3045303602171225,0.922389948271718,0.7368421052631579,0.9987637056403397,1.0,15/104,11.79%,H2AJ;TXNIP;H1-2;CDKN2AIP;PMM1;SLC7A11;STOM;RPS12;IRAK1;H2AW;RNF19B;MDM2;FAS;CEBPA;CASP1
170,prerank,KEGG_2021_Human__Hypertrophic cardiomyopathy,0.4402079481140651,0.9185193824639171,0.5662650602409639,0.9864117172440878,1.0,6/17,24.28%,TPM3;ATP2A2;ATP2A3;ACTB;PRKAB1;PRKAA1
171,prerank,MSigDB_Hallmark_2020__Myc Targets V1,-0.431325088957869,-0.9168719911013015,0.6718106995884774,0.9514363077525153,1.0,8/121,8.42%,HSP90AB1;YWHAQ;ETF1;HNRNPA2B1;EIF4G2;SNRPD2;YWHAE;PTGES3
172,prerank,KEGG_2021_Human__Alcoholism,0.3618160423170974,0.9153507230941191,0.6183206106870229,0.9715417625354809,1.0,6/42,5.21%,H2AJ;H3-3B;H3-3A;CALM3;MACROH2A1;H2AX
173,prerank,KEGG_2021_Human__Insulin signaling pathway,-0.448348615226093,-0.9043190677557478,0.6880630630630631,0.9743862673178291,1.0,6/57,12.94%,GRB2;MKNK2;CALM1;CALM2;CBL;GSK3B
174,prerank,KEGG_2021_Human__Mitophagy,-0.45357892379008447,-0.9012991272509697,0.6620370370370371,0.9742999288462362,1.0,2/42,1.54%,UBA52;ATF4
175,prerank,KEGG_2021_Human__SNARE interactions in vesicular transport,-0.49329219943842173,-0.9011129278446367,0.660024906600249,0.9677238979949576,1.0,6/22,16.88%,VAMP3;VAMP2;GOSR2;YKT6;SNAP23;USE1
176,prerank,KEGG_2021_Human__Longevity regulating pathway,-0.4434084533061173,-0.8947052200184853,0.6837899543378996,0.9747444153322358,1.0,9/47,22.73%,ATF4;CREB5;ADIPOR1;HRAS;ATG101;HSPA8;AKT2;AKT1;FOXO3
177,prerank,KEGG_2021_Human__Glycerophospholipid metabolism,0.36678343438938243,0.8937034845568912,0.6064516129032258,1.0,1.0,14/33,25.73%,DGKD;LPCAT3;LYPLA1;PLA2G5;ADPRM;PLAAT3;LPCAT1;LPIN1;PLA1A;CHPT1;LPIN2;AGPAT4;LPCAT2;GPD2
178,prerank,KEGG_2021_Human__Vasopressin-regulated water reabsorption,-0.4893406036176323,-0.8919342779027921,0.672090112640801,0.9738159939620408,1.0,2/23,9.31%,VAMP2;CREB5
179,prerank,KEGG_2021_Human__Dilated cardiomyopathy,0.418510005075975,0.887214183807602,0.6098484848484849,1.0,1.0,4/16,19.17%,TPM3;ATP2A2;ATP2A3;ACTB
180,prerank,KEGG_2021_Human__Apoptosis,0.31039646579088254,0.8812442005917424,0.8461538461538461,1.0,1.0,11/75,12.73%,TUBA1B;TUBA1A;CTSS;BIRC3;DAB2IP;TUBA1C;CYCS;TUBA4A;FAS;CTSL;NRAS
181,prerank,KEGG_2021_Human__Salmonella infection,-0.41358334118508544,-0.8796813692899381,0.7727272727272727,0.9931250871468941,1.0,11/148,8.40%,HSP90AB1;ARPC2;RAC1;TXN;TUBB2A;GAPDH;ELMO1;ARL8B;HSP90AA1;CASP7;DYNLRB1
182,prerank,KEGG_2021_Human__Autophagy,0.3142961957086218,0.8774719228650836,0.8518518518518519,1.0,1.0,2/70,0.67%,GABARAP;RAB7A
183,prerank,KEGG_2021_Human__Osteoclast differentiation,-0.4204703614666411,-0.8754524063498207,0.7196969696969697,0.9951879222646527,1.0,7/69,9.79%,RAC1;FCGR1A;GRB2;TGFBR2;TEC;PPP3CA;PPP3R1
184,prerank,KEGG_2021_Human__Insulin resistance,-0.4360996741458437,-0.8748188720511011,0.7110091743119266,0.989648567277011,1.0,5/45,16.38%,PTEN;PRKCB;CREB5;GSK3B;SREBF1
185,prerank,KEGG_2021_Human__Influenza A,0.29277467118839995,0.8727017904216751,0.96,0.9940174287811024,1.0,25/90,23.17%,HLA-DQA2;TMPRSS4;PYCARD;HLA-DRA;CYCS;SLC25A5;FAS;OAS3;CASP1;TLR4;IFIH1;DNAJC3;NXT1;TRADD;IFNAR1;ACTB;IRF7;PIK3CB;IKBKG;KPNA5;CCND3;RSAD2;ADAR;PIK3R1;STAT2
186,prerank,KEGG_2021_Human__N-Glycan biosynthesis,-0.49467724874860153,-0.8720728482507699,0.7073825503355705,0.9884348812615459,1.0,2/18,11.63%,DPM2;MAN2A1
187,prerank,KEGG_2021_Human__IL-17 signaling pathway,-0.43851671299521977,-0.8675562605320923,0.7176196032672112,0.9905055704858877,1.0,5/42,12.94%,HSP90AB1;CXCL2;HSP90AA1;USP25;GSK3B
188,prerank,KEGG_2021_Human__Complement and coagulation cascades,0.4012351499119447,0.8614926473182659,0.6831275720164609,1.0,1.0,4/20,7.54%,ITGAM;F12;CD55;ITGAX
189,prerank,KEGG_2021_Human__Citrate cycle (TCA cycle),-0.4863628180806445,-0.8490316691800632,0.7188328912466844,1.0,1.0,5/17,28.46%,FH;IDH1;MDH2;IDH3G;SDHD
190,prerank,MSigDB_Hallmark_2020__Inflammatory Response,0.29198739374120425,0.847149143635501,0.9375,1.0,1.0,17/93,19.86%,CYBB;IL18RAP;BEST1;CLEC5A;CD55;BST2;SLC28A2;ATP2A2;SEMA4D;CALCRL;CD69;TNFAIP6;IL7R;IFNAR1;MSR1;TLR2;IRF7
191,prerank,KEGG_2021_Human__Protein export,-0.48397725522404406,-0.8465380245584757,0.7155963302752294,1.0,1.0,6/18,26.00%,SEC61B;SEC61G;SPCS1;SEC63;SPCS3;SPCS2
192,prerank,KEGG_2021_Human__PD-L1 expression and PD-1 checkpoint pathway in cancer,-0.41743755373245156,-0.8438858728079618,0.7649667405764967,1.0,1.0,7/53,21.67%,PTEN;PPP3CA;PPP3R1;IFNGR2;HRAS;AKT2;AKT1
193,prerank,MSigDB_Hallmark_2020__mTORC1 Signaling,-0.3953491690347047,-0.8400372015549539,0.8137154554759468,1.0,1.0,20/119,17.57%,UBE2D3;GAPDH;ETF1;RAB1A;UFM1;INSIG1;PDAP1;SKAP2;SLC2A3;DDX39A;GSK3B;CD9;YKT6;ACTR3;SQLE;GLA;IFI30;HMGCR;PPIA;TXNRD1
194,prerank,KEGG_2021_Human__Cholesterol metabolism,0.3977514282142219,0.8378724509914819,0.6973684210526315,1.0,1.0,7/17,24.36%,MYLIP;NPC1;TSPO;VDAC3;SORT1;NCEH1;LIPA
195,prerank,KEGG_2021_Human__Spliceosome,-0.3959462004881415,-0.8364729623605736,0.8071278825995807,1.0,1.0,13/99,20.82%,SNRNP27;SNRPD2;FUS;SRSF4;LSM3;DDX46;PRPF38A;U2AF2;DDX23;RBM22;HSPA8;PRPF18;RP9
196,prerank,MSigDB_Hallmark_2020__DNA Repair,0.29405526187881065,0.8353189747550963,0.9166666666666666,1.0,1.0,8/78,8.63%,COX17;SDCBP;PNP;POLR1D;POLE4;TAF9;NT5C;NT5C3A
197,prerank,KEGG_2021_Human__Melanoma,-0.44315237733488877,-0.8334832183857181,0.7379746835443038,1.0,1.0,1/28,3.73%,PTEN
198,prerank,KEGG_2021_Human__RIG-I-like receptor signaling pathway,0.33651704084721745,0.8267941058977004,0.7847222222222222,1.0,1.0,19/33,35.74%,IFIH1;MAPK13;ISG15;OTUD5;CYLD;TRADD;IRF7;IKBKG;DDX3X;DHX58;DDX58;TANK;RNF125;RIPK1;IKBKE;STING1;NFKBIB;TRAF2;AZI2
199,prerank,KEGG_2021_Human__Herpes simplex virus 1 infection,0.2797489306561077,0.8192489471840168,0.9230769230769231,0.9989415599644126,1.0,19/94,20.03%,HLA-DQA2;TAB2;BIRC3;HLA-DRA;BST2;CYCS;IRAK1;EIF4EBP1;FAS;OAS3;RHEB;IFIH1;SRSF7;TRAF5;TRADD;IFNAR1;TLR2;IRF7;PIK3CB
200,prerank,KEGG_2021_Human__NF-kappa B signaling pathway,0.2970191123992516,0.8168876125383872,0.9080459770114943,0.9845442937921809,1.0,13/53,18.52%,LBP;TAB2;BIRC3;TIRAP;BCL10;PTGS2;IRAK1;TLR4;CSNK2A2;TRAF5;CYLD;TRADD;BCL2A1
201,prerank,KEGG_2021_Human__Shigellosis,-0.3782831131246702,-0.8047644663020721,0.8789743589743589,1.0,1.0,7/131,4.63%,UBA52;ARPC2;RAC1;UBE2D2;ROCK1;UBE2D3;ELMO1
202,prerank,KEGG_2021_Human__Rap1 signaling pathway,-0.38125192198399604,-0.7931348003236929,0.8529729729729729,1.0,1.0,7/71,11.19%,RAC1;RAP1A;CALM1;PRKCB;CALM2;RALB;GNAQ
203,prerank,KEGG_2021_Human__Cytosolic DNA-sensing pathway,0.3224379014379099,0.7831198304979405,0.8457446808510638,1.0,1.0,4/26,13.65%,POLR1D;PYCARD;CASP1;POLR3GL
204,prerank,MSigDB_Hallmark_2020__Interferon Gamma Response,-0.3648488404283308,-0.7824160402857817,0.9138804457953394,1.0,1.0,5/142,2.69%,IFIT1;PIM1;IFI35;FCGR1A;MARCHF1
205,prerank,KEGG_2021_Human__Salivary secretion,-0.4268678929545523,-0.7719779891430484,0.8151898734177215,1.0,1.0,6/19,11.67%,CALM1;PRKCB;CALM2;VAMP2;GNAQ;ATP1A1
206,prerank,KEGG_2021_Human__Peroxisome,0.32326471678145785,0.7654802143598468,0.9128205128205128,1.0,1.0,9/27,23.78%,SCP2;ACAA1;ACSL5;CROT;ACOT8;PEX2;XDH;CAT;MPV17
207,prerank,MSigDB_Hallmark_2020__Allograft Rejection,-0.36211187720806,-0.7653223504296349,0.8850574712643678,1.0,1.0,10/101,14.23%,RPL39;WAS;IL2RG;CAPG;LTB;PRKCB;UBE2N;MRPL3;ST8SIA4;IL12A
208,prerank,KEGG_2021_Human__Serotonergic synapse,-0.4226448504298091,-0.7647334778381013,0.8247162673392182,1.0,1.0,4/23,19.67%,PRKCB;GNAQ;HRAS;GNGT2
209,prerank,KEGG_2021_Human__Glutathione metabolism,0.35603017627194083,0.760628105046105,0.8280542986425339,1.0,1.0,6/18,18.00%,ANPEP;GPX1;GSTM1;GGCT;GCLM;TXNDC12
210,prerank,KEGG_2021_Human__Sphingolipid metabolism,-0.42942354047871995,-0.7543329892648944,0.8298429319371727,1.0,1.0,4/18,15.52%,SGPL1;ASAH1;UGCG;GLA
211,prerank,KEGG_2021_Human__Pathways of neurodegeneration,-0.3463251388008803,-0.7485599773462696,0.9678714859437751,1.0,1.0,31/244,12.94%,UBA52;RAC1;ATF4;CYTB;ND4;ND1;ATP5F1E;NDUFS7;COX1;TUBB2A;RAB1A;CHMP2B;ATP5F1C;NDUFB1;NDUFA1;CALM1;PSMB7;CASP7;FUS;PPP3CA;ND5;PRKCB;CALM2;NDUFA12;PPP3R1;TNFRSF1B;NRBF2;GNAQ;WIPI1;COX2;GSK3B
212,prerank,KEGG_2021_Human__Ferroptosis,-0.41920280996435183,-0.7466917407749819,0.8481675392670157,1.0,1.0,1/21,1.19%,SAT1
213,prerank,KEGG_2021_Human__Pertussis,-0.3802223409237441,-0.7419131517791288,0.8906605922551253,1.0,1.0,6/44,14.73%,C4A;CALM1;CASP7;CALM2;IL12A;LY96
214,prerank,KEGG_2021_Human__GnRH secretion,-0.41791507623671326,-0.7365872313007683,0.8502080443828016,1.0,1.0,5/19,21.67%,PRKCB;GNAQ;HRAS;AKT2;AKT1
215,prerank,KEGG_2021_Human__Gap junction,-0.4002462928892597,-0.7360746307450073,0.877370417193426,1.0,1.0,5/26,14.07%,GRB2;TUBB2A;PRKCB;GNAQ;SRC
216,prerank,MSigDB_Hallmark_2020__Apical Junction,-0.36055789453998,-0.7346954362488924,0.8880351262349067,1.0,1.0,5/56,7.42%,ARPC2;RSU1;PTEN;INSIG1;SKAP2
217,prerank,KEGG_2021_Human__Chagas disease,-0.35986335371152645,-0.7315514984565971,0.9055555555555556,1.0,1.0,14/56,29.17%,TGFBR2;GNAQ;IL12A;IFNGR2;TLR6;AKT2;AKT1;IRAK4;MAPK3;C3;TGFB1;TNF;GNA15;FOS
218,prerank,MSigDB_Hallmark_2020__Fatty Acid Metabolism,0.26154171125334347,0.7314246782767955,1.0,1.0,1.0,14/61,19.27%,LDHA;ACAA1;HSD17B10;MCEE;HSDL2;ACSL5;HSD17B11;RDH11;SDHC;ADIPOR2;ACOT8;CBR3;ACADL;YWHAH
219,prerank,KEGG_2021_Human__Amyotrophic lateral sclerosis,-0.3381237327343776,-0.7308815235500782,0.9707661290322581,1.0,1.0,23/211,9.88%,RAC1;ATF4;CYTB;ND4;ND1;ATP5F1E;NDUFS7;COX1;TUBB2A;RAB1A;HNRNPA2B1;CHMP2B;ATP5F1C;NDUFB1;NDUFA1;PSMB7;FUS;PPP3CA;UBQLN1;ND5;NDUFA12;PPP3R1;TNFRSF1B
220,prerank,KEGG_2021_Human__FoxO signaling pathway,-0.3542686851520093,-0.7271609261079625,0.8955555555555555,1.0,1.0,3/60,4.46%,GRB2;PTEN;TGFBR2
221,prerank,KEGG_2021_Human__Amoebiasis,-0.3729431573270835,-0.7222121583235841,0.8834134615384616,1.0,1.0,5/35,14.23%,CXCL2;PRKCB;GNAQ;VCL;IL12A
222,prerank,KEGG_2021_Human__Glycerolipid metabolism,-0.41065064243285865,-0.7217035928683451,0.8595800524934383,1.0,1.0,4/18,23.38%,GK;GLA;ALDH3A2;AGPAT1
223,prerank,KEGG_2021_Human__p53 signaling pathway,-0.3790792613519819,-0.7133662263044214,0.8635809987819733,1.0,1.0,2/28,13.29%,PTEN;COP1
224,prerank,KEGG_2021_Human__Ether lipid metabolism,-0.4186824700996883,-0.7060951395429659,0.8638814016172507,1.0,1.0,3/15,16.75%,PEDS1;PAFAH1B3;CEPT1
225,prerank,MSigDB_Hallmark_2020__heme Metabolism,-0.3338609775574579,-0.7020699585690281,0.9520255863539445,1.0,1.0,12/89,16.30%,PICALM;VEZF1;RIOK3;SEC14L1;MPP1;TNRC6B;CIR1;SYNJ1;MXI1;ADIPOR1;MGST3;HEBP1
226,prerank,KEGG_2021_Human__Drug metabolism,-0.38998529212992006,-0.7015219460094296,0.8848167539267016,1.0,1.0,8/20,23.40%,DPYD;MGST3;CMPK1;TPMT;CDA;GSTP1;NME3;HPRT1
227,prerank,KEGG_2021_Human__HIF-1 signaling pathway,-0.34252986529751567,-0.7008892827895224,0.9276974416017798,1.0,1.0,5/55,10.52%,GAPDH;MKNK2;IL6R;PRKCB;EP300
228,prerank,KEGG_2021_Human__Non-alcoholic fatty liver disease,-0.328104488971667,-0.698838346291605,0.9644351464435147,1.0,1.0,9/105,6.92%,RAC1;ATF4;CYTB;NDUFS7;COX1;IL6R;NDUFB1;NDUFA1;CASP7
229,prerank,KEGG_2021_Human__Toll-like receptor signaling pathway,-0.34577507933532436,-0.6983077661349084,0.9225589225589226,1.0,1.0,1/51,0.50%,RAC1
230,prerank,MSigDB_Hallmark_2020__Hypoxia,-0.33018503123663123,-0.6923335531676359,0.9508547008547008,1.0,1.0,10/78,15.88%,PIM1;GAPDH;SLC2A3;ZNF292;KLF7;FOSL2;TPST2;MXI1;CAVIN3;PRDX5
231,prerank,MSigDB_Hallmark_2020__KRAS Signaling Up,-0.3310569329851789,-0.6841058361589027,0.9545945945945946,1.0,1.0,9/65,15.61%,IL2RG;GALNT3;CBL;DOCK2;TNFRSF1B;ID2;FCER1G;LY96;PRELID3B
232,prerank,KEGG_2021_Human__Necroptosis,-0.3336693512977141,-0.6779994362098849,0.9556756756756757,1.0,1.0,7/70,11.11%,HSP90AB1;CHMP4B;VPS4B;CHMP2B;HSP90AA1;CHMP1A;GLUL
233,prerank,MSigDB_Hallmark_2020__Estrogen Response Early,-0.33307281385816295,-0.669333840790031,0.9404352806414662,1.0,1.0,5/50,15.52%,ELF1;RAB31;UGCG;SCNN1A;GLA
234,prerank,KEGG_2021_Human__Regulation of lipolysis in adipocytes,0.33184245531261697,0.668630247048702,0.9118773946360154,1.0,1.0,5/16,25.23%,PTGS2;PLAAT3;PIK3CB;PIK3R1;ADCY7
235,prerank,KEGG_2021_Human__C-type lectin receptor signaling pathway,-0.31758359910508155,-0.6527735252844942,0.9633225458468176,1.0,1.0,10/61,18.09%,CALM1;PPP3CA;CALM2;PPP3R1;SRC;IL12A;FCER1G;IRF9;HRAS;PAK1
236,prerank,KEGG_2021_Human__Thyroid cancer,0.2942979600478881,0.6488832804181492,0.9683257918552036,1.0,1.0,3/22,16.38%,TPM3;NRAS;TPR
237,prerank,KEGG_2021_Human__Tuberculosis,-0.31002572985016547,-0.6480862269817016,0.9729448491155047,1.0,1.0,10/93,14.50%,ATP6V0C;FCGR1A;CALM1;PPP3CA;CALM2;PPP3R1;EP300;SRC;IL12A;FCER1G
238,prerank,KEGG_2021_Human__Spinocerebellar ataxia,-0.3111091842997197,-0.6466550161466833,0.9808306709265175,1.0,1.0,14/73,24.44%,PSMB7;PRKCB;NRBF2;GNAQ;WIPI1;ATG101;PSMD7;AKT2;AKT1;XBP1;VDAC2;PSMD9;WIPI2;ATXN2L
239,prerank,KEGG_2021_Human__RNA transport,-0.31270612264684083,-0.6457156348158973,0.9829787234042553,1.0,1.0,9/77,19.46%,SUMO1;EIF4G2;FUS;FXR1;EIF4A1;SENP2;EIF1AY;NMD3;EEF1A1
240,prerank,MSigDB_Hallmark_2020__Myogenesis,-0.325807053771019,-0.6452074009615761,0.9655963302752294,1.0,1.0,10/43,20.92%,BIN1;NOTCH1;TNNC2;MYH11;FDPS;GABARAPL2;GSN;ITGB4;CKB;AKT2
241,prerank,KEGG_2021_Human__RNA degradation,-0.3253453411009244,-0.6405061904740729,0.967479674796748,1.0,1.0,7/37,24.59%,LSM3;ZCCHC7;DCPS;EXOSC3;WDR61;BTG2;EDC4
242,prerank,KEGG_2021_Human__mRNA surveillance pathway,-0.31354014046289214,-0.6350014542755339,0.9719730941704036,1.0,1.0,4/53,15.79%,ETF1;FUS;PPP2R5E;SSU72
243,prerank,KEGG_2021_Human__Small cell lung cancer,-0.32918230846664065,-0.6330495190240654,0.965435041716329,1.0,1.0,1/35,3.73%,PTEN
244,prerank,KEGG_2021_Human__Ribosome biogenesis in eukaryotes,0.27556980206134035,0.6330076160335018,0.9814814814814815,1.0,1.0,6/24,17.92%,MPHOSPH10;CSNK2A2;RIOK1;NOP10;NXT1;IMP4
245,prerank,MSigDB_Hallmark_2020__Estrogen Response Late,-0.3129965856938631,-0.6324258443541078,0.9854423292273237,1.0,1.0,7/52,15.52%,LTF;RAB31;ID2;CD9;DNAJC1;SCNN1A;GLA
246,prerank,KEGG_2021_Human__Neuroactive ligand-receptor interaction,0.2724963490161143,0.6214610523871861,0.9764150943396226,1.0,1.0,7/22,21.84%,UTS2;FPR2;CALCRL;CYSLTR1;TSPO;CNR2;GPR35
247,prerank,MSigDB_Hallmark_2020__Xenobiotic Metabolism,-0.30286813745744656,-0.6209561472312658,0.9800664451827242,1.0,1.0,14/61,24.42%,PTGES3;COMT;AQP9;ID2;PINK1;CDA;IDH1;PSMB10;GABARAPL1;ECH1;ARG1;HPRT1;ACOX1;SSR3
248,prerank,KEGG_2021_Human__Adipocytokine signaling pathway,-0.3262541199803637,-0.6174901709697639,0.9730392156862745,1.0,1.0,4/29,21.67%,TNFRSF1B;ADIPOR1;AKT2;AKT1
249,prerank,KEGG_2021_Human__Bladder cancer,0.2689061614996339,0.6014700812163444,0.9822222222222222,1.0,1.0,3/21,12.73%,MMP9;MDM2;NRAS
250,prerank,MSigDB_Hallmark_2020__Bile Acid Metabolism,0.2651827292386442,0.5962350064093966,0.9864253393665159,0.9906061895786465,1.0,6/21,16.82%,SCP2;NPC1;ACSL5;HSD17B11;CROT;GCLM
251,prerank,KEGG_2021_Human__Inflammatory bowel disease,-0.3248495212574588,-0.5842724955592736,0.9754204398447607,1.0,1.0,3/23,16.61%,IL2RG;IL12A;IFNGR2
252,prerank,MSigDB_Hallmark_2020__Cholesterol Homeostasis,-0.3013626588034224,-0.5662381529867037,0.985663082437276,1.0,1.0,8/29,22.07%,CD9;SQLE;MVD;HMGCR;FDPS;ANXA5;ANTXR2;ECH1
253,prerank,KEGG_2021_Human__Epstein-Barr virus infection,-0.25933442380627114,-0.5464601873305387,1.0,1.0,1.0,1/109,0.50%,RAC1
254,prerank,KEGG_2021_Human__Morphine addiction,-0.316144621499413,-0.5399464804254507,0.983957219251337,1.0,1.0,1/15,8.46%,PRKCB
255,prerank,MSigDB_Hallmark_2020__Pperoxisome,-0.267213452981806,-0.5193385684915803,0.9965156794425087,1.0,1.0,6/38,19.21%,VPS4B;ITGB1BP1;PRDX5;FDPS;HRAS;IDH1
256,prerank,KEGG_2021_Human__Measles,-0.22764247313585112,-0.46958425143072396,1.0,0.9991744977822995,1.0,9/78,21.67%,IL2RG;GSK3B;IL12A;IRF9;HSPA8;CD46;AKT2;CDKN1B;AKT1
